← Back to patent-cliff list
Dexamethasone sodium phosphate sustained release (Taiwan Liposomal Company)
Tier C — Watch / tradeDexamethasone sodium phosphate sustained release (Taiwan Liposomal Company)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GR
Indications (approved)：Knee arthritis
Regional status
US
Phase III
2019-11-26
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dexamethasone sodium phosphate sustained release (Taiwan Liposomal Company)?
Approved indications include: Knee arthritis.
When does the Dexamethasone sodium phosphate sustained release (Taiwan Liposomal Company) patent expire?
No public expiry year is available for Dexamethasone sodium phosphate sustained release (Taiwan Liposomal Company) yet; this page updates once verified.
How do I get a quote for Dexamethasone sodium phosphate sustained release (Taiwan Liposomal Company) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07